



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

FSC231

Cat. No.:	HY-117772
CAS No.:	1215849-96-9
Molecular Formula:	C ₁₃ H ₁₀ Cl ₂ N ₂ O ₃
Molecular Weight:	313.14
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



SOLVENT & SOLUBILITY

In Vitro	DMSO : 50 mg/mL (159.67 mM; Need ultrasonic)				
		Solvent Concentration	Mass		
	Preparing Stock Solutions		1 mg	5 mg	10 mg
		1 mM	3.1935 mL	15.9673 mL	31.9346 mL
		5 mM	0.6387 mL	3.1935 mL	6.3869 mL
	10 mM	0.3193 mL	1.5967 mL	3.1935 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (7.98 mM); Clear solution				

BIOLOGICAL ACTIVITY

Description	FSC231 is a PSD α 95/DLG/ZO α 1 (PDZ) domain inhibitor of PICK1. FSC231 has analgesic effects ^[1] .
IC ₅₀ & Target	PICK1 ^[1] .
In Vitro	FSC231 (50 μ M) blocks binding between GluR2 and PICK1 in COS7 cells ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	FSC231 (78.40 μ g/kg in total, daily, seven times, i.p., 3 h before Paclitaxel) alleviates the Paclitaxel (HY-B0015) α induced neuralgia of rats ^[1] . FSC231 (39.2 μ g/kg/day, i.p., for 4 weeks) inhibits the development of diabetic cardiomyopathy in rats by inhibiting ROS generation and apoptosis partly via PICK1/eNOS/cGMP pathway ^[3] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Paclitaxel (HY-B0015) induced neuralgia of rats ^[1]
Dosage:	78.40 µg/kg in total
Administration:	i.p., daily, seven times, completed at 3 h before Paclitaxel
Result:	Reversed the changes of inflammatory cytokines (IL6, TNFα and IL10). Inhibited the phosphorylation levels of GSK3β and ERK1/2.

REFERENCES

- [1]. Zhang X, et al. FSC231 alleviates paclitaxel-induced neuralgia by inhibiting the interactions between PICK1 and GluA2 and activates GSK-3β and ERK1/2. *Brain Behav.* 2021 Nov;11(11):e2380.
- [2]. Thorsen TS, et al. Identification of a small-molecule inhibitor of the PICK1 PDZ domain that inhibits hippocampal LTP and LTD. *Proc Natl Acad Sci U S A.* 2010 Jan 5;107(1):413-8.
- [3]. Cai Fei, et al. GW27-e1146 PICK1 inhibition restores myocardial injury by suppressing reactive oxygen species generation and apoptosis in diabetic rats. *J Am Coll Cardiol.* 2016 Oct, 68 (16_Supplement) C67.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA